MADISON, Wis.--(BUSINESS WIRE)--Promega Corporation announced today its intent to develop the Promega OncoMate™ microsatellite instability (MSI) Assay as a companion diagnostic test for retifanlimab, ...

MADISON, Wis.--(BUSINESS WIRE)--Promega Corporation today announced FALCO biosystems of Kyoto, Japan, a core business company of FALCO HOLDINGS, working in collaboration with Promega microsatellite ...

FDA Approves Promega OncoMate® MSI Dx Analysis System as Companion Diagnostic for KEYTRUDA® in Combination with LENVIMA® In Advanced Endometrial Carcinoma Promega MSI technology will aid in the ...

CDx IVD kit will be used to identify patients with the MSI biomarker who may be eligible for potential treatment with Jemperli (dostarlimab-gxly) MADISON, Wis.--(BUSINESS WIRE)--Promega Corporation ...

Page Jump: ===== 1 - MSI's take on Intel's X58 2 - Some of that tri-channel goodness 3 - SLI, CrossFire and more MSI's take on Intel's X58 MSI's Eclipse has been doing the rounds for a while, but the ...

The U.S. Food and Drug Administration (FDA) has approved the Promega OncoMate ® MSI Dx Analysis System as a companion diagnostic designed to identify patients with microsatellite stable (MSS; defined ...

CDx IVD kit will be used to identify patients with the MSI biomarker who may be eligible for potential treatment with Jemperli (dostarlimab-gxly) Promega Corporation today announced it plans to ...

Promega Corporation announced today its intent to develop the Promega OncoMate microsatellite instability (MSI) Assay as a companion diagnostic test for retifanlimab, Incyte's anti-PD-1 drug candidate ...

(MENAFN- AETOSWire) (BUSINESS WIRE ) -- The U.S. Food and Drug Administration (FDA) has approved the Promega OncoMate ® MSI Dx Analysis System as a companion diagnostic designed to identify patients ...

Promega Corporation, a leader in providing innovative solutions and?technical support?to the life sciences industry, announced that the US Food and Drug Administration (FDA) has approved the OncoMate ...